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Using a monoclonal antibody against human HLA-DR 
antigens and OKT6, we investigated by indirect immu-
nofluorescence the distribution of Langerhans cells in 
normal human skin and involved and uninvolved skin 
from patients with psoriasis before, during, and after 
systemic aromatic retinoid administration. In parallel, 
enumeration of HLA-DR and of OKT6+ cells was also 
performed. In involved psoriatic epidermis the distribu-
tion of positive cells was disturbed; OKT6+ cells were 
reduced in number, as were HLA-DR+ cells which were 
seen in clusters. In control skin sections, a regular pat-
tern of fluorescent dendritic epidermal cells was noted. 
In normal-appearing human skin, in nonlesional pso-
riatic skin, but not in diseased psoriatic skin, the number 
of OKT6+ cells per epidermal section surface unit was 
higher than that of HLA-DR expressing cells. Changes 
in the number and distribution of OKT6 and HLA-DR+ 
cells in psoriatic involved epidermis were corrected by 
oral retinoid treatment. 
Langerhans cells (LC) are known to play a major role in skin 
immune reactions [1-4] and have also been conjectured to 
participate in the regulation of epidermal keratinization [5,6]. 
Alterations of the immune ·system have been found associated 
with psoriasis [7-10]. 
Notably, changes in the frequency and distribution of LC in 
the epidermis have been described [11,12]. However, these 
reports were not based on the use of specific methods of 
identification and thus remain to be confirmed. 
LC beru: the HLA-DR (!a-like) antigens [13], as do some 
other cell types such as indeterminate cells in the skin, macro-
phages, B lymphocytes, and some activated T cells [14,15]. 
Recently, ·the monoclonal antibody OKT6 has been shown to 
recognize a specific antigen expressed only by LC and indeter-
minate cells in the skin [16-21]. 
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Abbreviations: 
AT: antetreatment 
e.s.s.u.: epidermal section surface unit (0.0576 mm2) 
FITC: fluorescein isothiocyanate 
HPS: healed psoriatic skin 
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LC: Langerhans cell(s) 
MCAB: monoclonal antibody(ies) 
NICS: noninvolved control skin 
NIPS: noninvolved psoriatic skin 
NHS: normal human skin 
PBS: phosphate-buffered saline 
PT: posttreatment 
X: average number of positive cells per epidermal section surface 
unit (0.0576 mm2) 
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In the present study, we investigated the qualitative and 
quantitative distribution of LC in psoriatic epidermis before 
and under systemic treatment with the aromatic retinoid Ro 10 
9359 (etretinate- Tigason), which is known to affect favorably 
disordered keratinization [22] and has been shown to exhibit a 
stimulatory effect on several cell types including LC [23]. In 
parallel, LC distribution was analyzed in normal human skin, 
and uninvolved skin from patients. Studies were conducted by 
immunofluorescence (IF) using 2 monoclonal antibodies 
(MCAB): an anti-HLA-DR and OKT6 MCAB. The ATPase 
stain of split epidermis specimens was performed in pru·allel. 
Data show that the abnormal distribution ofLC in t h e diseased 
psoriatic epidermis is corrected by retinoid administration. 
MATERIALS AND METHODS 
Patients and Controls 
Fifteen male adult patients with chronic psoriatic plaques of mod-
erate activity (peripheral spreading) and extension were treated with 
aromatic retinoid (etretinate- Tigason), 1 mg/kg body weight per day. 
No other systemic or local treatment was used. Positive results were 
observed in 12 patients, who showed amelioration in all skin lesions 
and rapid clearing of some within 6 weeks of treatment. Three patients 
dropped out from the study; 2 did not come for consecutive examina-
tions; the other 1 had an exacerbation of his lesions after 3 weeks, and 
the treatment was discontinued. 
Control groups consisted of 15 healthy male age-matched volunteers 
(normal human skin: NHS) who did not receive retinoid and 5 male 
age-matched patients (2 with keratoses of the palms and soles, 3 with 
lichen planus (noninvotved control skin: NICS) treated with retinoid, 
1 mg/ kg body weight per day. 
Shin Biopsies 
Biopsies from involved psoriatic skin (IPS) and noninvolved psoriatic 
skin (NIPS) were petformed (forearm extensory surface) before, at 
various times during· (1, 2, 3, 4 weeks), and after complete local healing 
of the studied plaques (healed psoriatic skin: HPS) in patients with 
psoriasis. NHS biopsies and NICS biopsies before and after 6 weeks of 
retinoid were also petformed in controls (same location) . Surgical 
biopsies of approximately 5 X 10 mm were taken under local anesthesia 
(1% Xylocaine) and divided into 3 parts; one was immediately frozen in 
]jquid nitrogen for IF studies, another fixed in Baker's solution for 
control microscopic examination, and the third (5 X 5 mm) used for 
A TPase stain. 
Indirect Immunofluorescence 
Immunoreagents: Orthoclone OKT6 MCAB produced by Ortho 
Immunobiology Ltd, Raritan, New Jersey, was kindly provided by 
Cilag-Chimie, France. Its specificity for LC among other cells in the 
epidermis has been described previously [16,17]. BL2 anti-HLA-DR 
MCAB was produced by J. Brochier (INSERM U 80, Lyon, France) 
after fusion and subsequent cloning of spleen cells from BALB/c mice 
immunized by human B cells from chronic lymphocytic leukemia with 
SP20 myeloma cells. Fluorescein isothiocyanate (FITC)-conjugated 
goat antimouse lg (Meloy Lab. Inc., Springfield, Virginia) (F /P ratio 
2.9) was used in the second step of IF technique. 
Staining procedure: Frozen skin sections (4-5 J.Lm) were fixed in 
acetone (10 min at -20°C), incubated with the appropriate MCAB 
(final dilution 1: 10) at 37°C for 45 min, rinsed in phosphate-buffered 
saline (PBS) 2 x 10 min. Sections were then incubated in FITC 
conjugate (1:20) at 37°C (for 45 min) , rinsed twice, and mounted in 
July 1983 OKT6 AND HLA-DR+ CELLS IN PSORIASIS WITH RETINOID ADMINISTRATION 11 
buffered glycerin. The slides were viewed under a Zeiss IF microscope 
and positive cells (+ cells) counted by means of a n ocular square grid 
covering, under 40x objective magnification, 0.0576 mm2 of skin section 
surface. 
Cell quantification: Each grid side was divided into 10 parts such 
that the grid field contained 100 smaller squares. A tota l of 40 adjacent 
grid fields of epidermal sections were examined on 2 slides, each bearing 
3 skin sections for every skin specimen and each MCAB used. This 
represents about 9.6 mm of continuous section. As the exact proportions 
between IF+ and IF- epidermal cells depends on epidermal thickness, 
we evaluated the number of IF+ cells per epidermal section surface 
unit (e.s.s.u. ) where e.s.s.u. = 0.0576 mm2• This mean number of IF+ 
cells per e.s.s.u. (:X) was equal to the total number of IF+ cells counted 
in all the fields divided by the sum of the epidermal thicknesses 
measw-ed along the grid side of each field examined. Only dendritic 
cells exhibiting a bright fluorescent cytoplasm and a dark nucleus were 
counted as positives; isolated dendJ·ites were not scored. 
ATPase Cytochemical Staining Method 
An ATPase stain was performed on EDTA-separated sheets of 
epidermis according to the technique previously described by Juhlin 
and Shelley [24]. Values of ATPase+ cells counted under 25X magni-
fication were expressed per mm2 of epidermal surface. 
Statistical Analysis 




In NHS, OKT6+ dendritic cells were seen only in the epider-
mis, as an intense continuous fluorescent network in the supra-
basal malpighian layers. No OKT6+ cells were observed in the 
dermis. The fluorescence pattern of HLA-DR+ epidermal cells 
was similru·, although the intensity of the fluorescence was 
weaker. Strongly fluorescent HLA-DR+ cells could, however, 
be found in dermal papillae and in the upper dermis, among 
perivascular infiltrating cells. A similar distribution was ob-
served in NIPS and NICS. In IPS, the distribution of OKT6 
and of HLA-DR+ cells was uneven. OKT6+ cells (Fig 1) were 
rare and predominantly distributed around hair follicle orifices. 
No OKT6+ cells were noted in the dermis. HLA-DR+ cells 
were present as dense clusters of brightly fluorescent cells in 
the epidermis, mostly above the elongated dermal papillae, and 
in the dermal papillae themselves (Fig 2). In large areas of the 
epidermis, no fluorescent cells were seen. In none of the IPS 
Frc 1. Involved epidermis from a patient with pson asrs (IPS) 
stained with OKT6 MCAB. Rare OKT6+ cells ru·e seen in the epider-
mis. x 400. 
Frc 2. Involved epidermis from a patient with psoriasis (IPS) 
stained with anti-HLA-DR MCAB. Clusters of epidermal HLA-DR+ 
cells and grouped HLA-DR+ cells in a dermal papilla. x 400. 
Frc 3. Healed psoriatic involved skin (HPS) ta ined wi th 0KT6 
MCAB; regular distribution of dendJ·itic epidermal OKT6+ cells. S im-
ilar findings in normal human skin. X 400. 
sections did we observe a granulru· epidermal intercellular stain-
ing. 
During retinoid treatment, changes were observed in IPS 
with a trend toward IF patterns observed in NHS. Dermal 
HLA-DR+ cells progressively decreased in number in psoriatic 
involved skin; in HPS, posttreatment NICS, and NIPS, a reg-
ular distribution of epidermal OKT6 and of HLA-DR+ cells 
was observed, which was similru· to that noted in NHS (Figs 3, 
4). Dermal HLA-DR+ cells were then rare. Histologic controls 
(hemalun and eosin) of IPS before and after treatment showed 
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typical features of psoriasis vulgaris in IPS sections and their 
absence in HPS. The presence of mild dermal mononuclear 
infiltrates was the only morphologic feature found in HPS that 
differed from that noted in NHS. 
Cell Enumeration 
Table I shows the OKT6+ and HLA-DR+ cell enumeration 
CX) noted in NHS and in NICS, NIPS, and IPS before and after 
retinoid treatment. In NHS, but also NICS and NIPS before 
treatment, HLA-DR+ X were lower than OKT6+ X. However 
this difference was only significant in NHS (p < 0.01) (Table 
I). In contrast, in IPS, OKT6+ X was lower than HLA-D2 X 
(p < 0.001). In IPS before treatment OKT6 X and HLA-DR+ 
FIG 4. flealed psoriatic involved skin (HPS) stained with anti-HLA-
DR MCAB. HLA-DR+ epidermal dendritic cells are clistributed regu-
larly in the malpighian layers, as in normal human skin; only rare HLA-
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FIG 5. Enumeration of OKT6+ epidermal cells (OKT6+ X) and of 
HLA-DR+ epidermal cells (HLA-DR+ X) in IPS (-- ) and NIPS 
(· - - - -) before (0), during (J, 2, 3, 4 weeks), and after (HPS) oral 
retinoid administration. I = X ± SD. The data are expressed as cells 
per epidermal section surface unit (0.0576 mm2). 
TABLE I. Enumeration of OKT6+ cells and HLA -DR+ cells in the epidermis: normal human skin (NHS), noninvolved control skin (NICS), 
noninvolved psoriatic skin (NIPS), and involved psoriatic shin (IPS) before (antetreatrnent = AT) and after (posttreatment= PT) retinoid 





OKT6+ X and HLA-
DR+X 
NHS 
37.22 ± 12.00" 
23.85 ± 9.01" 
p < 0.01 1' 
Statistical significances between NICS, 
NIPS or IPS vs. NHS 
"X±SD. 
" Statistical significances. 
c NS: not significant. 
NICS 
AT 
19.79 ± 8.8 
11.20 ± 7.36 
NS"" 
p < 0.01" 
(OKT6+ X) 
p < 0.02 
(HLA-DRX) 
PT 
30.53 ± 7.78 





22.77 ± 8.13 
15.67 ± 5.98 
NS 





28.12 ± 5.76 





4.26 ± 1.79 25.81 ± 5.71 
8.32 ± 3.29 14.48 ± 4.02 
p < 0.001 p < 0.001 
p< 0.001 NS 
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X were both lower than in NHS, as also noted in NIPS and 
NICS (Table I) . OKT6+ X and HLA-DR+ X increased grad-
ually in IPS during treatment (Fig 5) until no significant differ-
ences were noted between HPS and NHS (Table I). Slight but 
nonsignificant increases were observed in NIPS (Fig 5). After 
treatment, no significant differences were noted between values 
in NIPS and NICS and values in NHS (Table I). Changes with 
retinoid treatment were significant only in IPS (Table I). In 
HPS, OKT6+ X was higher than HLA-DR X (p < 0.001), as 
found in NHS, NIPS, and NICS (Table I). 
Finally, as compared to results obtained in NHS, the ATP-
ase+ cell enumeration in untreated IPS plaques was extremely 
doubtful because of the irregular and insufficient dendritic cell 
coloration in the highly acanthotic and papillomatous epider-
mis. However, a low ATPase+ cell density was observed in 
NIPS before treatment (82.3 ± 23.69) when compared to NHS 
105.75 ± 34.47 (p < 0.01); HPS or posttreatment NIPS values 
were not significantly different from those found in NHS (re-
spectively: 112.02 ± 9.79, 125.53 ± 17.45, and 105.75 ± 34.47). 
DISCUSSION 
In the present study, 2 MCAB were used to determine the 
distribution and number of epidermal cells expressing the T6 
and HLA-DR antigens in normal and psoriatic skin. Our data 
show that the distribution and number of these cells are altered 
in IPS and that these changes are corrected in HPS after a 
successful oral retinoid treatment. 
The ATPase stain method did not enable us to evaluate 
properly the distribution ofLC in IPS. Therefore, we performed 
IF on skin sections using 2 MCAB as markers of these cells. 
Previous studies have indicated that OKT6 binds specifically 
to LC and indeterminate cells in the skin [16,17,20,21] and that 
LC and indeterminate cells express the HLA-DR antigens in 
normal human epidermis [13,15]. The staining pattern observed 
in each case provided us with a qualitative evaluation of t he 
distribution of these cells in skin sections. Their numeration 
was expressed as the mean number of IF+ cells per epidermal 
section sw-face unit (X) in order to remove variations resulting 
from differences in epidermal thickness [25]. 
In normal-appearing epidermis (NHS, NIPS, NICS), HLA-
DR-bearing cells and OKT6+ cells appeared as dendritic cells 
with a regular distribution in the suprabasal layers of the 
epidermis. Our quantitative analysis indicated lower numbers 
ofHLA-DR+ epidermal cells than OKT6+ cells, as has recently 
been documented by others [18,19]. 
In fact, correlating T6+ with HLA-DR+ dendritic epidermal 
cells in normal human skin has shown that anti-OR-antibodies 
underestimate the number of LC in normal human skin [17-
19]. In the present study, only on IPS sections was OKT6+ X 
found to be lower than HLA-DR+ X. Recent data suggest that 
under pathologic conditions, HLA-DR antigens may be iden ti-
fied by IF on keratinocytes [26,27], giving an intercellular, 
"pemphigus-like" staining. Although a similar phenomenon 
could conceivably account for the relatively higher HLA-DR+ 
X in IPS epidermis, in none of IPS sections examined did we 
observe such a staining pattern. Another possibility is t hat in 
IPS, some HLA-DR+ cells correspond to exocytic infiltrating 
lymphocytes or histiocytes [11]. In fact, only immunoperoxidase 
staining and irnmunoelectron microscopic examination of IPS 
sections could permit the definite distinction between HLA-
DR+ epidermal cells and infiltrating HLA-DR+ mononuclear 
cells. 
Whatever the problems in interpreting HLA-DR+ X in IPS, 
the significant reduction in OKT6+ cells can be taken as a 
direct indication of changes in the distribution and frequency 
of LC (and indeterminate cells) of the epidermis, sin ce OKT6 
has been shown to be a more specific marker for these cells in 
the skin [17,19]. Correction of these defects was noted with oral 
retinoid treatment. In HPS, the IF patterns were similar to that 
noted in NHS, with T6+ cells more numerous than HLA-DR+ 
cells. Whether these returns toward normal are directly due to 
some pharmacologic effects of retinoid or related only to the 
normalization of the process of keratinization remains unclear. 
In fact, increases in cell number were also noted in NIPS and 
NICS during treatment. Studies by Tsambaos and Orfanos [23] 
noted ultrastructural changes in LC from patients undergoing 
retinoid therapy suggestive of a metabolic activation by the 
drug. 
Besides their role in immunologic processes, the involvement 
of LC in the proliferation and keratinization of epidermis has 
been suggested by various observations [5,6]. There seems to 
exist an inverse relationship between proliferative events and 
the number ofLC [28], also between the degree of parakeratosis 
and LC density [29-31]. It is not surprising therefore that 
aromatic retinoids that correct defects of keratinization may 
also normalize the distribution of LC in psoriasis. 
The possibility does exist that defects in LC themselves play 
a role in the pathogenesis of the disease [32]. However, whether 
the observed changes in LC number and distribution in psoriatic 
lesions are causal or secondary to the disease cannot be an-
swered here. The return to a normal LC distribution in parallel 
with the improvement of lesions with retinoid treatment does 
not necessarily signify that retinoids exert their action through 
an effect on LC. UVB [33], PUV A [34-37], and topical corti-
costeroids [34,35], which are also successful therapies in pso-
riasis, deplete LC from the skin. This study has exploited 
specific MCAB to demonstrate marked changes in the presence 
of antigen-bearing cells in psoriasis and their return to normal 
upon retinoid treatment. However, as in all such studies, it 
must be recognized that the presence or absence of a membrane 
marker does not mean that a given cell type is hyperfunctional, 
nonfunctional, or absent. 
We thank P. Ledger, P h .D., for his help in the p1·eparation of the 
manuscript . 
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Complement-Activating Immune Deposits in Systemic Lupus 
Erythematosus Skin 
W. RAY GAMMON, M.D., CAROLYN C. M ERRITT, M.D., DAVID C. HENKE, M.D., TED RoBINSON, B.S., 
NANCY HENLEY, M .D. , AND LAURA DEANGELO, M.D. 
Department of Dermatology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, U.S.A. 
Immune d eposits a t the cutaneous basement mem-
brane zone are a characteristic feature of systemic lupus 
erythematosus. Previous studies u sing immunofluores-
cent methods to detect complement components have 
provided evidence that some deposits contain immune 
complexes capable of activating complement. However, 
this important biologic property of complexes has not 
been detected or measured using functional assays, and 
it has not been determined whether immune deposits 
can activate complement at the basement membrane 
zone. 
In this study ~mmune deposits in biopsies oflupus skin 
have been examined u sing direct immunofluorescence 
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Abbreviations: 
BMZ: basement membrane zone 
C3: third component of complement 
for the third component of complement (C3) to detect 
complement deposited in vivo. In addition, the deposits 
have been studied using the leukocyte attachment assay 
and indirect C3 binding immunofluorescence to detect 
and measure complement activation at the basement 
membrane zone in vitro. The results show that comple-
ment activation occurs at the basement membrane in 
some but not all lupus skin containing immunoglobulin 
deposits, that deposits differ quantitatively in their abil-
ity to activate complement, and that direct C3 immuno-
fluorescence is a relatively insensitive method for de-
tecting complement-activating complexes. The results 
DC: disease control group 
FITC: fluorescein isothiocyanate 
GBSS: Gey's balanced salt solution 
Ig: immunoglobulin 
LA: leukocyte attachment 
LAA: leukocyte attachment assay 
NHC: normal control group 
NHS: normal human serum 
NHSi: normal human serum inactivated 
PEL: peripheral blood leu kocytes 
PBS: phosphate-buffered saline 
SLE: Systemic lupus erythematosus 
